On February 5, 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb Company. Breyanzi is a chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. [Read more…]
T Cells For Immune Defense: CAR-T Cell Therapies in 2025
Can T cells be an effective approach to cancer treatment? CAR T-cell therapy, as this cutting-edge treatment is called, uses a patient’s own immune system to help fight cancers in the body. The result is a natural treatment that proves effective against a variety of blood cancers and may have hope for other cancers in the future as well.
T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens.
Using T Cells For Cancer Treatment
In this article:
- CAR-T Cell Therapy Treatments for Treatment of Cancer
- What Causes Cancer?
- How Does the Immune System Work – and What Are Its Limits?
- What Is Immunotherapy?
- Are There Different Types of Immunotherapy?
- What Are T Cells?
- What Is CAR-T Cell Therapy?
- How Does CAR-T Cell Therapy Work?
- Who Is CAR-T Cell Therapy Right For?
- Why Doesn’t CAR-T Cell Therapy Work for Solid Tumors?
- Are There Any Risks?
- What Are the Benefits of CAR-T?
- How Effective Is CAR-T Treatment?
- Progress in CAR-T Cell Therapy Development
VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
CHICAGO, IL, January 11, 2025 — VectorBuilder’s partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) on January 11, 2025. VectorBuilder has provided highly customized end-to-end CDMO solutions to support this clinical pipeline. [Read more…]
Autolus Latest Competitor in Global CAR-T Frenzy with FDA Approval of Aucatzyl
On November 8, 2024, the U.S. FDA issued a historic approval of the seventh CAR-T cell therapy to be approved in the U.S. and the 11th CAR-T therapy to be approved globally. This approval was for Autolus Inc.’s Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Autolus is a U.K. biotech company that develops novel gene-modified T cell therapies for the treatment of cancer. [Read more…]
Is the CAR-T Cell Therapy Craze Driving Pharma Investment?
Without a doubt, the cell therapy industry is coming of age. In addition to growing numbers of cell therapy clinical trials, numerous cell therapy products have been approved by regulatory agencies worldwide and 150+ cell therapy companies are competing within the global marketplace. These metrics are extremely important because they indicate that the market for cell therapy products is expanding.
However, one of the most telling trends within the industry is a growing interest among Big Pharma in cell therapy companies. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 13
- Next Page »